Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or…
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer…
Preliminary data from the Phase 1/2 trial of PORT-2 demonstrates favorable safety and tolerability as a monotherapy with translational data…
MINNEAPOLIS, June 06, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on…
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing…
OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizuresData demonstrate OV329 has the potential…
Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with PFS at 1 year demonstrated…
- Data from the Parker Institute for Cancer Immunotherapy and Cancer Research Institute multi-center Phase 2 PRINCE trial demonstrated that…
Positive results of preceding Phase 2 trial to be featured in oral presentation at the American Society of Clinical Oncology…
Inclacumab is a novel P-selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive crises (VOCs) and readmissions due…